HOME >> BIOLOGY >> NEWS
Loyola decides to test new blood substitute in trauma patients at the scene of injury

MAYWOOD, Ill. Loyola University Health System plans to test PolyHeme, an investigational oxygen-carrying blood substitute designed to increase survival of critically injured and bleeding trauma patients at the scene of injury, beginning July 1, 2004, as part of a national clinical trial.

Loyola's Institutional Review Board for the Protection of Human Research Subjects (IRB) approved the clinical trial following extensive public education activities. Since February, Loyola has been conducting a number of community outreach efforts, including meetings with community leadership; open forums with members of the public; placing public notices in community newspapers; and distributing flyers in schools, churches, grocery stores and public health centers. Loyola is one of 20 Level I trauma centers participating in the trial nationwide and the only one in Illinois.

"If the blood substitute works the way we hope it will, it could be the first major advance since the introduction of saline, or salt water, to replace volume after blood loss, around the time of World War I," said Dr. Richard L. Gamelli, principal investigator, chair of the Department of Surgery and professor of trauma surgery, Loyola University Chicago Stritch School of Medicine.

The community outreach efforts were necessary in this study because the nature of the potential patients' injuries extreme shock would typically prevent having informed consent. However, consent will be sought whenever possible.

Currently, patients can only receive blood in a hospital and that means a trauma victim may need to wait up to an hour for a transfusion following transport to the hospital and being typed and cross-matched.

"Saline, the current standard of care, helps us restore a patient's blood pressure but does not deliver oxygen, a critical nutrient to prevent organ damage in the brain, heart, lungs, liver and kidneys," Gamelli explained.

"Carrying blood in an am
'"/>

Contact: Stephen Davidow
sdavidow@lumc.edu
708-216-8232
Loyola University Health System
27-May-2004


Page: 1 2 3 4

Related biology news :

1. Familiarity decides if wolf spider loves em or eats em
2. Experimental drug shown to block mutant protein causing blood disease
3. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
4. A probable cause for high blood pressure identified - shows links with diabetes
5. Probing the surface of white blood cells to enhance immune system medicine
6. Streptococcus infects humans by thwarting blood clotting
7. Strep disrupts blood clotting to infect humans
8. Nucleic acid-amplification testing further safeguards nations blood supply
9. Hopkins scientists use blood proteins to detect ovarian cancer
10. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels
11. Oxygen sensing in worms may hold key to healthy blood pressure in humans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... , ... September 03, 2020 , ... ... data, today announced that an extensive third-party assessment of the company’s security practices ... when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... solutions for drugs, biologics, cell and gene therapies, and consumer health products, today ... PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September ...
(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... BINGHAM FARMS, Mich. (PRWEB) , ... August 12, ... ... International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... Corrigan, President and CEO has been named one of the 100 most inspiring ... sectors, PharmaVoice 100 honorees are selected based on how they have inspired their ...
(Date:7/31/2020)... Ariz. (PRWEB) , ... July 29, 2020 , ... R3 ... joint injections for only $3950. With 50 million stem cells total, patients may choose ... stem cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. ... can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI ... two switches in a push-pull configuration; yielding fast fall time for a capacitive ...
Breaking Biology Technology:
Cached News: